BPX-401 / Bellicum - LARVOL DELTA

Bellicum announces oral presentation at ASH showing improved potency and control with CIDeCAR T-Cell therapies (Bellicum Press Release) - "Bellicum Pharmaceuticalspresented preclinical data from studies of its CIDeCAR™ CAR T-cell technology, including product candidate BPX-401, in an oral presentation at the 57th American Society of Hematology (ASH) Annual Meeting today...The addition of the MC costimulatory domain led to a significant increase in in vivo activation and persistence of the CIDeCAR CAR T cells when compared to CARs constructed with conventional costimulatory domains CD28 and 4-1BB...Two additional poster presentations1,2 at ASH featured the Company’s GoCAR-T and GoTCR technologies."

Conference • Preclinical • Oncology